Associated Papers
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
The complexity of tobacco smoke-induced mutagenesis in head and neck cancer.
Torrens L et al.
Nature Genetics, 2025
Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: A retrospective cohort study.
Iwasaki T et al.
Cancer Science, 2024
Nrf2, A Target for Precision Oncology in Cancer Prognosis and Treatment.
Ngo HKC et al.
Journal of Cancer Prevention, 2023
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome.
El Khoury LY et al.
Clinical Epigenetics, 2023
Utilization of cytologic cell blocks for targeted sequencing of solid tumors.
Vormittag-Nocito E et al.
Cancer Medicine, 2023
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.
Garcia-Prieto CA et al.
Bioinformatics (oxford, England), 2022
An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy.
Lin J et al.
Frontiers in Immunology, 2022
Spatially interacting phosphorylation sites and mutations in cancer.
Huang KL et al.
Nature Communications, 2021
Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate.
Pandey A et al.
Nature Communications, 2020
Somatic Evolution in Non-neoplastic IBD-Affected Colon.
Olafsson S et al.
Cell, 2020
A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population.
Kang T et al.
Breast Cancer Research : Bcr, 2020
Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L et al.
Redox Biology, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas.
Beinse G et al.
Plos One, 2019
A catalogue of somatic NRF2 gain-of-function mutations in cancer.
Kerins MJ et al.
Scientific Reports, 2018
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Chen F et al.
Nature Communications, 2017
Cross-cancer profiling of molecular alterations within the human autophagy interaction network.
Lebovitz CB et al.
Autophagy, 2015
Genomic structure and variation of nuclear factor (erythroid-derived 2)-like 2.
Cho HY
Oxidative Medicine and Cellular Longevity, 2013
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin.
Kim YR et al.
The Journal of Pathology, 2010